Drug Type Small molecule drug |
Synonyms Pexacerfont (USAN/INN), BMS-562086 |
Target |
Action antagonists |
Mechanism CRHR1 antagonists(Corticotropin-releasing factor receptor 1 antagonists) |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization- |
Active Organization- |
License Organization- |
Drug Highest PhaseDiscontinuedPhase 2/3 |
First Approval Date- |
Regulation- |
Molecular FormulaC18H24N6O |
InChIKeyLBWQSAZEYIZZCE-SNVBAGLBSA-N |
CAS Registry459856-18-9 |
| KEGG | Wiki | ATC | Drug Bank |
|---|---|---|---|
| D10022 | Pexacerfont | - |
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Generalized anxiety disorder | Phase 3 | United States | 01 Jul 2007 | |
| Anxiety Disorders | Phase 2 | United States | 01 Oct 2010 | |
| Irritable bowel syndrome with diarrhea | Phase 2 | United States | 01 Dec 2006 | |
| Depressive Disorder, Major | Phase 2 | United States | 01 Nov 2005 | |
| Binge-Eating Disorder | Phase 1 | United States | 01 Jun 2012 |
Phase 2 | 70 | (Pexacerfont) | xgcbbnmbkd(hfvztavmwl) = xdrxhnuoxq konqkrjuwa (qpqypvtovm, 2.48) View more | - | 10 Dec 2015 | ||
Placebo (Placebo) | xgcbbnmbkd(hfvztavmwl) = wptwdxukdr konqkrjuwa (qpqypvtovm, 2.60) View more | ||||||
Phase 2/3 | 260 | qsqaoqthzj(lpfgpxukku) = vjoisqtnnv ywdhkvblxx (pcmqbweugl ) | Negative | 01 May 2010 | |||
Placebo | qsqaoqthzj(lpfgpxukku) = tjuwaccjuy ywdhkvblxx (pcmqbweugl ) |





